* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Long non-coding RNA (lncRNA) LIPCAR predicts survival in heart
Survey
Document related concepts
Saturated fat and cardiovascular disease wikipedia , lookup
Cardiovascular disease wikipedia , lookup
Electrocardiography wikipedia , lookup
Hypertrophic cardiomyopathy wikipedia , lookup
Remote ischemic conditioning wikipedia , lookup
Heart failure wikipedia , lookup
Antihypertensive drug wikipedia , lookup
Coronary artery disease wikipedia , lookup
Arrhythmogenic right ventricular dysplasia wikipedia , lookup
Cardiac surgery wikipedia , lookup
Cardiac contractility modulation wikipedia , lookup
Transcript
Long non-coding RNA (lncRNA) LIPCAR predicts survival in heart failure patients Reference Number: 15-00366 Challenge Heart Failure (HF) belongs to the major common diseases and occurs in about 2% of the population worldwide. The primary reasons for HF are myocardial infarction, hypertension and cardiomyopathy leading to cardiac remodeling and an insufficient cardiac output. LncRNAs are extracellular nucleic acids and represent a novel class of regulatory molecules. Recent studies identified lncRNAs as promising biomarkers for the detection of various cancers, e.g. prostate cancer. In contrast, the diagnostic potential of lncRNAs in cardiac diseases is largely unknown. Technology Due to dynamically regulation of the myocardial transcriptome in pathological processes, lncRNAs emerge as new and specific biomarkers for the diagnosis of cardiovascular diseases. Recent studies identified the mitochondria-derived lncRNA LIPCAR as a very promising biomarker for the prognosis of survival in heart failure patients. LIPCAR enables the early prediction of the future development of cardiac remodeling in patients who had an episode of myocardial infarction. Further, LIPCAR levels are associated with future cardiovascular deaths in heart failure patients independent of other predictors. For this reasons, LIPCAR enables the timely diagnosis of the disease course and renders possible a therapy of the patient at an early stage. Thus, LIPCAR is the first available lncRNA biomarker for the assessment and prognosis of disease progression in heart failure patients. Commercial Opportunity In-licensing or collaboration for further development is possible. Developmental Status Studies with blood plasma samples from 800 patients with chronic heart failure or left ventricular (LV)-remodeling were conducted for identification and validation of regulated cardiovascular lncRNAs. Patent Situation An international PCT application (PCT/EP2015/055713) has been filed with priority of 2014. Further Reading Circulating levels of LIPCAR associated with cardiac death Licensing Contact Dr Torben Söker Technology Scout T: +49 511 53289-18 F: +49 511 53289-29 [email protected] Ascenion GmbH Herzogstraße 64 D-80803 München T: +49 89 318814-0 F: +49 89 318814-20 [email protected] www.ascenion.de Berlin Braunschweig Hamburg Hanover Munich Neuherberg Kumarswamy R, Bauters C, Volkmann I, Maury F, Fetisch J, Holzmann A, Lemesle G, de Groote P, Pinet F, Thum T. 2014. Circulating Long Noncoding RNA, LIPCAR, Predicts Survival in Patients With Heart Failure. Circ Res. 114:1569-1575. Powered by TCPDF (www.tcpdf.org)